Biosimilars/Biobetters Pipeline Directory        
The most comprehensive and cost-effective follow-on biopharmaceuticals (biosimilars, biobetters and biogenerics) pipeline resource 

  • Find competing products and companies; product/API licensing sources; collaborators and partners; customers for your products, technologies and services
  • Over 1,550 product records:  875+ biosimilars, 525+ biobetters, 149 reference products; plus 700 involved company records [12/26/2017]
  • Available in multiple formats:
    • Directory/book/PDF format - PDF file ready for use or printing; 1-time delivery of current data
    • Web database (Products and Companies) subscription - for those needing online access and updates; plans for individuals and company-wide access
  • Developed by the author of BIOPHARMA:  Biopharmaceuticals in the U.S. and European Markets, still the only information resource/reference specializing in biopharmaceuticals but no longer being updated and now is the "The Reference Products' Reference." 
  • Sales/fulfillment handled by BioPlan Associates, Inc.
  • Satisfaction guaranteed!  Full refund within 1 month, e.g., if you do not learn information that critically affects your company.

Description/Flyer:  Further information
Users Guide
Contact/Order/Inquiry form
Enter password for database access: followed by CR/enter

Biosimilars/Biobetters Pipeline Database - Top Level Data (as of 1/1/2018)

  • product entries = 1,552
  • pipeline products (biosimilars + biobetters) = 1,403
  • biosimilars = 877
  • biobetters = 526
  • ref. products = 146
  • companies = 700
The Biosimilars/Biobetters Pipeline Directory covers only recombinant proteins (great majority) and other cell culture/fermentation-manufactured protein products (e.g., vaccines, blood/plasma and cellular products not included). 
[Note, biosimilar and biobetter U.S. and EU launchable dates (patent, data and market exclusivity expirations) are reported for the reference products in BIOPHARMA: Biopharmaceutical Products in the U.S. and European Markets, "The Reference Products' Reference]." 

Near-term economic impact includes biosimilars sooner or later in the U.S. and European markets for the <50, nearly all recombinant, mostly monoclonal antibody, products with over $1 billion/year sales, and 20+ others with sales over $500 million/year. 

The table above shows country or regions and the numbers of biosimilars and biobetters associated with companies based (with headquarters) in these countries/regions.

Note, multiple companies are often involved with each product (developers, partners, licensees, etc.). Marketed products are here indexed by whether they appear primarily on track for initial or primary marketing in developed or developing country markets.

Some Popular Targeted Reference Products
[No. of biosimilars by reference product]
Epoetin alfa 90
Neupogen 77
Interferons (alfa) 75
Insulin and analogs 71
Rituxan 51
Herceptin 54
Humira 45
Avastin 40
Somatropins 37
Enbrel 36
Neulasta 31
Remicade 21
Lantus 15
Interferons (beta) 32
Cancer indications 490
mAbs, mAb fragments      334

Companies With the Largest Biosimilars Pipelines (10 or more)

Harvest Moon Pharmaceuticals USA, Inc. 28
Bioviz Technologies Pvt. Ltd. 28
Pfizer 21
BioXpress Therapeutics S.A. 20
Reliance Life Sciences Pvt. Ltd. 18
Creative Biomart Inc. 15
Dong-A Pharmaceutical. 15
Chemo Group (Grupo Insud ) 15
Inbiopro Solutions Pvt Ltd. 14
LG Life Sciences Ltd. 14
Mylan Labs. 14
Bio Sidus S.A. 13
Biocon Ltd. 13
BioPartners GmbH (Bioton) 13
Intas Biopharmaceuticals Ltd. 13
Dr. Reddy's Labs. 13
AXXO GmbH 12
Sandoz AG/Novartis AG 12
SciGen Ltd. (Bioton) 12
Amega Biotech 12
BioGenomics Ltd. 11
Green Cross Corp. 11
BioGenomics Ltd. 11
Zydus Cadilla Healthcare Ltd. 11
Viropro Inc. 11
Cassara Biotech 10
Biocad Biotechnological Co. 10
Siam Bioscience 10 Information Resources A variety of unique follow-on biopharmaceutical-related information resources are available or planned:

Some related articles by the database author:

Need a Consultant With Biosimilars Expertise? - Contact Biotechnology Information Institute for world-class expertise concerning biopharmaceutical information, products, technologies, and related market, technology and policy assessments.  

    Contact information: